

1 16. (Once amended) A method for treatment of a hyperproliferative disorder in a
2 patient, the method comprising administering to a patient a therapeutically effective dose of a
3 fusion polypeptide that comprises [comprising a fusion of] a DNA binding domain of a
4 transcription factor and a functional growth suppression domain of a [, the transcription factor
5 comprising a DNA binding domain, and a] retinoblastoma (RB) polypeptide [, the RB
6 polypeptide comprising a growth suppression domain].

1 17. (Once amended) The method of claim 16, wherein the fusion polypeptide
2 [protein] is encoded by a nucleic acid delivered to the patient.

1 18. (Reiterated) The method of claim 16, wherein the transcription factor is E2F.

1 19. (Reiterated) The method of claim 18, wherein the cyclin A binding domain
2 of the E2F is deleted or nonfunctional.

1 20. (Reiterated) The method of claim 16, wherein the RB is RB56.

1 21. (Reiterated) The method of claim 16, wherein the RB is wild type RB56.

1 22. (Once amended) The method of claim 16, wherein the functional growth
2 suppression domain of the RB polypeptide comprises from about amino acid residue 379 to
3 about amino acid residue 928 (SEQ ID NO:4).

1 23. (Once amended) The method of claim 16, wherein the functional growth
2 suppression domain of the RB polypeptide comprises at least one substitution of amino acid
3 residues selected from the group consisting of 2, 608, 612, 788, 807, and 811.

1 24. (Once amended) The method of claim 18, wherein the E2F polypeptide
2 comprises about amino acid residues 95 to about 286 (SEQ ID NO:1).

1 25. (Once amended) The method of claim 18, wherein the E2F polypeptide
2 comprises about amino acid residues 95 to about 194 (SEQ ID NO:1).

1 26. (Once amended) The method of claim 16, wherein the fusion polypeptide
2 comprises EF2 amino acid residues from about 95 to about 194 (SEQ ID NO:1) operatively
3 linked to RB amino acid residues from about 379 to about 928 (SEQ ID NO:4).

1 27. (Reiterated) The method of claim 18, wherein the E2F-RB fusion
2 polypeptide is expressed under the control of a tissue-specific promoter.

1 28. (Reiterated) The method of claim 27, wherein the tissue specific promoter is
2 a smooth muscle actin promoter.

1 29. (Reiterated) The method of claim 16, wherein the hyperproliferative
2 disorder is cancer.

1 30. (Reiterated) The method of claim 29, wherein the cancer is bladder cancer.

1 31. (Reiterated) The method of claim 29, wherein the hyperproliferative
disorder is restenosis.

1 32. (Once amended) The method of claim 31, wherein the [E2F-RB] fusion
2 polypeptide is administered after angioplasty.

1 33. (Once amended) The method of claim 32, wherein the [E2F-RB] fusion
2 polypeptide is administered as a coating on an angioplasty device.

1 34. (Reiterated) The method of claim 17, wherein the nucleic acid is
2 administered after angioplasty.

1 35. (Reiterated) The method of claim 17, wherein the nucleic acid is
2 administered as a coating on an angioplasty device.

1 36. (Reiterated) The method of claim 17, wherein the nucleic acid is inserted in
2 an adenovirus vector.

Please add the following new claim 37.

1 37. The method of claim 16, wherein the fusion polypeptide lacks a functional
2 cyclin A-kinase binding domain of the transcription factor.